|
ABECMA
(2021)
|
Cell (autologous, modified) |
Celgene Corporation, a Bristol-Myers Squibb Company |
CAR T cells recognize the B-cell maturation antigen (BCMA) and kill BCMA-expressing tumor cells. A lentiviral vector, developed by bluebird bio, is used to engineer the CAR T cells.
|
ADSTILADRIN
(2022)
|
Adenovirus |
Ferring Pharmaceuticals A/S |
A recombinant adenovirus (rAd-IFNa/Syn3) delivers human interferon alfa-2b cDNA into the bladder epithelium. Treats patients with certain types of bladder cancer.
|
|
ALLOCORD
(2013)
|
Cell (allogeneic) |
SSM Cardinal Glennon Children's Medical Center
|
Blood cell transplant derived from umbilical cord and placenta.
|
BREYANZI
(2021) |
Cell (autologous, modified) |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
|
CAR T cells engineered with lentivirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of large B-cell lymphoma. |
CARVYKTI
(2022)
|
Cell (autologous, modified)
|
Janssen Biotech, Inc.
|
CAR T cells engineered with lentivirus to attack BCMA-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory multiple myeloma. |
CLEVECORD
(2016)
|
Cell (allogeneic)
|
Cleveland Cord Blood Center
|
Transplant of hematopoietic progenitor cells (HPCs) from human cord blood.
|
DUCORD
(2012) |
Cell (allogeneic)
|
Duke University School of Medicine |
Transplant of HPCs from human cord blood.
|
GINTUIT
(2012) |
Cell (allogeneic)
|
Organogenesis Inc. |
Cellularized scaffold for topical application to a surgically created wound bed to treat certain mucogingival conditions. |
HEMACORD
(2011)
|
Cell (allogeneic)
|
New York Blood Center |
Transplant of HPCs from human cord blood.
|
HEMGENIX
(2022)
|
AAV5 |
CSL Behring LLC, UniQure |
Recombinant AAV5 delivers F9 to treat patients with certain kinds of Hemophilia B. |
HPC, Cord Blood
(2012)
|
Cell (allogeneic)
|
Clinimmune Labs, University of Colorado Cord Blood Bank |
Transplant of HPCs from human cord blood.
|
HPC, Cord Blood - MD Anderson Cord Blood Bank
(2018)
|
Cell (allogeneic)
|
MD Anderson Cord Blood Bank |
Transplant of HPCs from human cord blood.
|
HPC, Cord Blood - LifeSouth
(2016)
|
Cell (allogeneic)
|
LifeSouth Community Blood Centers, Inc. |
Transplant of HPCs from human cord blood.
|
HPC, Cord Blood - Bloodworks
(2016)
|
Cell (allogeneic)
|
Bloodworks |
Transplant of HPCs from human cord blood.
|
IMLYGIC
(2015) |
HSV-1 |
BioVex, Inc., a subsidiary of Amgen Inc. |
Recombinant HSV-1 delivers GM-CSF to treat patients with certain unresectable melanoma lesions. |
KYMRIAH
(2017)
|
Cell (autologous, modified) |
Novartis Pharmaceuticals Corporation |
CAR T cells engineered with lentivirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory follicular lymphoma.
|
LAVIV
(2011)
|
Cell (autologous, expanded) |
Fibrocell Technologies |
Fibroblasts to improve the appearance of moderate to severe nasolabial fold wrinkles. |
LUXTURNA
(2017)
|
AAV2 |
Spark Therapeutics, Inc. |
Recombinant AAV2 delivers RPE65 to treat patients with RPE65-mutation-associated retinal dystrophy. |
MACI
(2016)
|
Cell (autologous, expanded) |
Vericel Corp. |
Cellularized scaffold to repair cartilage defects of the knee. |
PROVENGE
(2010) |
Cell (autologous, activated/expanded) |
Dendreon Corp. |
Antigen presenting cells are activated and used to treat certain types of prostate cancer. |
RETHYMIC
(2021)
|
Cell (allogeneic) |
Enzyvant Therapeutics GmbH |
Thymus tissue implant to improve immune function in patients with certain types of congenital athymia. |
SKYSONA
(2022)
|
Cell (autologous, modified) |
bluebird bio, Inc. |
Hematopoietic stem cells engineered with Lenti-D vectors that express the ABCD1 gene. Treats patients with a kind of cerebral adrenoleukodystrophy. |
STRATAGRAFT
(2021) |
Cell (allogeneic) |
Stratatech Corporation |
Cellularized scaffold of keratinocytes and dermal fibroblasts in murine collagen to treat patients with some types of thermal burns. |
TECARTUS
(2020)
|
Cell (autologous, modified) |
Kite Pharma, Inc. |
CAR T cells engineered with gammaretrovirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory mantle cell lymphoma. Differs from YESCARTA in that the engineered T cells are enriched for activity against certain B cells. |
YESCARTA
(2017)
|
Cell (autologous, modified)
|
Kite Pharma, Inc. |
CAR T cells engineered with gammaretrovirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory large B-cell lymphoma.
|
ZYNTEGLO
(2022)
|
Cell (autologous, modified)
|
bluebird bio, Inc. |
Hematopoietic stem cells engineered with a lentivirus, LentiGlobin BB305, to express HBB. Treats patients with certain types of ß-thalassemia. |
ZOLGENSMA
(2019)
|
AAV9 |
Novartis Gene Therapies, Inc. |
Recombinant AAV9 delivers SMN1 to treat patients with certain types of spinal muscular atrophy. |